Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

It is the third leading cause of cancer-related deaths globally, with the highest number of cases in East Asia and South ...

REDWOOD CITY, CA, USA I March 31, 2025 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development ...

For the first time, scientists have systematically analyzed somatic mutations in stomach lining tissue to unpick mutational ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

My message to everyone is simple—take the first step, seek professional advice, and remember, "The best investment you can ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

“I’ve been really, really passionate about my work, but the situation in the US is so stressful,” says a postdoctoral researcher who studies cancer ... is from South Asia but has spent ...

The research was published in the oncology journal Cancer Cell ... including Xiangya Hospital of Central South University in Changsha, Hunan province, and Hubei Cancer Hospital in Wuhan, Hubei ...

BENGALURU, India (AP) — Most of the world has dirty air, with just 17% of cities globally meeting air pollution guidelines, a report Tuesday found.